ASCO 2026's cancer-detection milestone; FDA embeds AI in drug review

Multicancer blood tests, immunotherapy trends, and FDA's AI overhaul headline a busy weekend in medicine.

• Sunday, 31 May: PATHFINDER 2 multicancer early-detection data presented at ASCO 2026
• Sunday, 31 May: ASCO 2026 — Cancer vaccines and immunotherapy combinations signal a new era
• Friday, 29 May: AI transfer learning identifies cancer-risk genes in breast and prostate tissue
• Thursday–Saturday, 28–30 May: FDA consolidates 40+ siloed systems into a single AI review platform
• Thursday, 28 May: North Carolina Senate advances bill protecting patients from AI-only insurance denials
• Saturday, 30 May: Simple ingredient swaps could move meals 47% closer to nutritional targets—at lower cost